Bradenton, Florida Clinical Trials

A listing of Bradenton, Florida clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 32 clinical trials
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

To evaluate the safety and tolerability of ERAS-601. To determine the ERAS-601 Maximum Tolerated Dose (MTD) and/or recommended dose (RD) as a monotherapy and in combination with a MEK inhibitor. To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with a MEK inhibitor.

Sarah Cannon Research Institute (Florida Cancer Specialists)
 (4.8 away) Contact site
  • 0 views
  • 31 Jul, 2021
  • +5 other locations
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim …

carcinoma
measurable disease
combinations
gemcitabine
investigational treatment
GSK Investigational Site
 (5.4 away) Contact site
  • 0 views
  • 26 Jan, 2021
  • +29 other locations
Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

The purpose of this study is to assess the safety and pharmacokinetics of MK-5890 when administered alone and in combination with pembrolizumab (MK-3475) in adults with advanced solid tumors. The initial course of MK-5890 monotherapy or MK-5890 plus pembrolizumab combination therapy will be for up to 35 administrations (approximately 2 …

mk-3475
pembrolizumab
lung carcinoma
antineoplastic
cancer
Florida Cancer Specialists ( Site 0002)
 (4.8 away) Contact site
  • 283 views
  • 02 Aug, 2021
  • +11 other locations
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and …

carcinoma
immunostimulants
nivolumab
fluoropyrimidine
docetaxel
GSK Investigational Site
 (4.8 away) Contact site
  • 0 views
  • 15 Jun, 2021
  • +122 other locations
Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors

The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in participants with resected solid tumors and in combination with pembrolizumab in participants with unresectable solid tumors.

carcinoma
measurable disease
alopecia
major surgery
cancer
Florida Cancer Specialists
 (5.4 away) Contact site
  • 40 views
  • 15 Jun, 2021
  • +6 other locations
Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma. The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.

Florida Cancer Specialists
 (5.4 away) Contact site
  • 0 views
  • 18 Apr, 2021
  • +6 other locations
A Study of CC-99712 a BCMA Antibody-Drug Conjugate in Subjects With Relapsed and Refractory Multiple Myeloma

Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in subjects with relapsed and refractory multiple myeloma (MM). The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-99712, …

immunotherapeutic agent
measurable disease
immunoglobulins
proteasome inhibitor
neutrophil count
Florida Cancer Specialists
 (5.4 away) Contact site
  • 63 views
  • 27 Feb, 2021
  • +9 other locations
RBN-2397 an Oral PARP7 Inhibitor in Patients With Solid Tumors FIH MAD Study

RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the cell from sending a signal (Type 1 interferon) that tells the immune system that something is wrong and …

cancer
breast cancer
solid tumour
lymphoma
solid tumor
SCRI-Sarasota/Florida Cancer Specialists
 (5.4 away) Contact site
  • 0 views
  • 31 Jul, 2021
  • +7 other locations
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT543.

Florida Cancer Specialist
 (5.4 away) Contact site
  • 80 views
  • 01 Aug, 2021
  • +22 other locations
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors

Florida Cancer Specialists
 (6.3 away) Contact site
  • 38 views
  • 27 Jan, 2021
  • +3 other locations